Wellington Management Group LLP Has $2 Million Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Wellington Management Group LLP raised its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 20.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 138,767 shares of the company’s stock after purchasing an additional 23,660 shares during the quarter. Wellington Management Group LLP owned 0.10% of Centessa Pharmaceuticals worth $1,995,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after acquiring an additional 3,194 shares in the last quarter. Barclays PLC boosted its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. Lord Abbett & CO. LLC boosted its holdings in shares of Centessa Pharmaceuticals by 1.3% during the 1st quarter. Lord Abbett & CO. LLC now owns 446,196 shares of the company’s stock valued at $6,416,000 after acquiring an additional 5,701 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of Centessa Pharmaceuticals by 33.2% during the 4th quarter. Squarepoint Ops LLC now owns 26,806 shares of the company’s stock valued at $449,000 after acquiring an additional 6,685 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insiders Place Their Bets

In other news, General Counsel Iqbal J. Hussain sold 12,000 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $14.02, for a total value of $168,240.00. Following the completion of the transaction, the general counsel directly owned 105,386 shares of the company’s stock, valued at approximately $1,477,511.72. This trade represents a 10.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $13.86, for a total value of $138,600.00. Following the completion of the transaction, the insider directly owned 122,279 shares of the company’s stock, valued at approximately $1,694,786.94. This trade represents a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 171,322 shares of company stock valued at $2,472,814. Insiders own 7.09% of the company’s stock.

Centessa Pharmaceuticals Stock Up 1.4%

Shares of NASDAQ:CNTA opened at $16.79 on Friday. The firm has a market cap of $2.25 billion, a P/E ratio of -9.38 and a beta of 1.48. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.60 and a 12-month high of $19.09. The business has a fifty day simple moving average of $15.70 and a 200 day simple moving average of $14.47.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Truist Financial assumed coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a “buy” rating and a $30.00 price objective on the stock. Oppenheimer assumed coverage on Centessa Pharmaceuticals in a report on Friday. They set an “outperform” rating and a $40.00 price objective on the stock. Wall Street Zen downgraded Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Chardan Capital reissued a “buy” rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Finally, Needham & Company LLC began coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a “buy” rating and a $35.00 price objective on the stock. Eleven analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $31.50.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.